IMMU-13. PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
Carrie Myers(Seattle Children's Hospital), Nicholas A. Vitanza(Seattle Children's Hospital), Andrea Timpanaro(Center for Cancer and Blood Disorders), Aquene N. Reid(Seattle Children's Hospital), Edward Z. Song(Unknown), Rebecca Gardner(Seattle Children's Hospital), Michael Meechan(Seattle Children's Hospital), Kamila Gwiazda(Seattle Children's Hospital), Matthew C. Biery(Seattle Children's Hospital), Michael Baldwin(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital), Alex Chen(Nutrasource), Joshua A. Gustafson(Seattle Children's Hospital)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754